CYCLOPHARM LIMITED — Capital/Financing Update 2012

Nov 8, 2012

9 November 2012

==> picture [167 x 59] intentionally omitted <==

NOTICE UNDER SECTION 708AA(2)(F) OF THE CORPORATIONS ACT 2001 (CTH)

On 9 November 2012, Cyclopharm Limited ( Company ) announced a fully underwritten renounceable prorata entitlement offer to raise approximately $2.1 million before offer costs.

The net proceeds of the offer will go towards funding the operating costs of Cyclopet, support the legal proceedings Cyclopet has commenced against the Australian Nuclear Science and Technology Organisation and to fund the commencement of the Technegas clinical trial in the United States. While the market for products manufactured by Cyclopet has been encouraging in 2012, competition from government owned enterprises requires additional capital to support this venture.

The United States Food and Drug Administration ( FDA ) clinical trial has commenced with the first installation in October this year. The FDA clinical trial costs are estimated to cost approximately US$4.0 million in total with expenditure of US$0.8 million expected within the next 12 months. The balance of the FDA clinical trial costs is expected to be funded through a subsequent capital raising next year.

Under the offer, existing eligible shareholders of the Company can subscribe for 1 share for every 4 shares in the Company that they hold at the record date at an issue price of $0.18 per share ( Rights Issue ).

There will also be a shortfall facility, under which eligible shareholders will have the ability to subscribe for additional shares in the Company, which may be issued from any shortfall under the Rights Issue. The Rights Issue will be fully underwritten by CVC Managers Pty Ltd ( Underwriter ).

The Rights Issue will be open to shareholders on the record date of 7.00pm (Sydney time) on 19 November 2012 with a registered address in Australia and New Zealand ( Eligible Shareholders ).

The Company gives notice under section 708AA(2)(f) of the Corporations Act 2001 ( Act ) as modified by Australian Securities and Investments Commission Class Order 08/35 (CO 08/35) that:

• 1 The Company will offer the shares under the Rights Issue without disclosure to Eligible Shareholders under Part 6D.2 of the Act.

• 2 The Company is providing this notice under paragraph 708AA(2)(f) of the Act as notionally modified by CO 08/35.

• 3 As at the date of this notice, the Company has complied with:

  • 3.1 the provisions of Chapter 2M of the Act as they apply to the Company; and

  • 3.2 section 674 of the Act.

• 4 As at the date of this notice, there is no excluded information as defined in section 708AA(8) and section 708AA(9) of the Act which is required to be disclosed by the Company.

• 5 The effect the issue of shares under the Rights Issue will have on the control of the Company, and the consequences of that effect, will depend on a number of factors, including:

  • 5.1 investor demand and the level of support for the Rights Issue; and

  • 5.2 the level of trading (if any) in rights.

The Directors cannot speculate the extent to which the full entitlements under the Rights Issue will be accepted by the Eligible Shareholders, the level of rights trading or the levels of voting power after completion of the Rights Issue. However, they make the following observations.

legal/40704926_1

‐ 2 -

Potential dilution generally of existing shareholders

If every security holder takes up their full entitlement under the Rights Issue and there is no rights trading, the Rights Issue will have no material effect on the control of the Company. However, if not every security holder subscribes for their full entitlement under the Rights Issue or there is rights trading, the existing security holders who do not take up the entitlements under the Rights Issue will be diluted upon the issue of shares.

Potential increase in voting power in the Company of CVC and its associates

Stinoc Pty Ltd ( Stinoc ) (the Company's largest shareholder) and the Underwriter (CVC Managers Pty Ltd), are both wholly owned subsidiaries and associates of ASX listed investment company, CVC Limited ( CVC ).

Their voting power in the Company is currently as follows:

Holder	Nature of relevantinterest	Relevant interest inExisting Shares	Voting Power (%)
Stinoc Pty Ltd	Registered holder ofshares	8,894,973	19.13
CVC Managers PtyLtd	Associate of Stinoc PtyLtd	Nil	Nil
CVC Limited	Controller of its whollyowned subsidiariesStinoc Pty Ltd and CVCManagers Pty Ltd	8,894,973(indirectly throughassociation withStinoc Pty Ltd)	19.13

CVC and its associates may increase significantly their voting power in the Company as a result of the Rights Issue.

The maximum voting power of CVC and its associates could increase to up to approximately 35.30% after completion of the Rights Issue, if:

• no Eligible Shareholders, except Stinoc, subscribed for their entitlements under the Rights Issue;

• there was no rights trading; and

• the Underwriter subscribed for the shortfall under the Rights Issue (assuming Stinoc takes up its full entitlement of 2,223,744 Shares).

The table below provides an illustration of the potential increases in the shares held by CVC and its associates on the basis of the assumptions above and subject to the effects of rounding:

Holder	Shares before RightsIssue	Shares before RightsIssue	Shares after Rightsissue - assuming 50%shortfall	Shares after Rightsissue - assuming 50%shortfall	Shares after Rightsissue - assuming 100%shortfall	Shares after Rightsissue - assuming 100%shortfall
	Number	%	Number	%	Number	%
Stinoc PtyLtd	8,894,973	19.13	11,118,717	19.13	11,118,717	19.13
CVCManagersPty Ltd	Nil	Nil	4,700,970	8.09	9,401,939	16.17
RemainingShareholders	37,607,758	80.87	42,308,727	72.78	37,607,758	64.70
Total	46,502,731	100%	58,128,414	100%	58,128,414	100%

Table 1: Potential increase in shareholding

legal/40704926_1

‐ 3 -

In these circumstances, the increase in voting power of CVC and its associates, as a group, would be as follows:

Holder	Before Rightsissue	Voting power afterRights issue -assuming 50%shortfall	Voting power afterRights issue -assuming 100%shortfall
CVC Group	19.13%	27.22%	35.30%
Remaining Shareholders	80.87%	72.78%	64.70%

Table 2: Potential increase in voting power of CVC Group

The Company has taken steps to minimise as far as possible the potential increase in the voting power of CVC and its associates by:

• pricing the Rights Issue at a level to make it commercially attractive to participate

• structuring the Rights Issue so that the entitlements are renounceable and may be sold to new investors wishing to subscribe for shares and

• including a shortfall facility which enables eligible shareholders to apply to shares in addition to their entitlement.

Intentions of CVC Limited

CVC has advised the Company that if CVC obtained control of the Company:

• CVC's present intention is to exercise its voting power to cause the Company to continue its current business in the ordinary course and to pursue the strategies advised to the market; and

• CVC has no present intention to change the direction or business of the Company, to enter into any related party transactions with the Company, to materially restructure the employment arrangements of the Company, or to redeploy any of its fixed assets.

==> picture [110 x 28] intentionally omitted <==

Mr James McBrayer Managing Director

legal/40704926_1